Multinational pharmaceutical companies, such as MSD, Pfizer, Roche and AZ, are about to compete over immune antibodies
As domestic Phase 3 clinical trials have actively been made for immune antibodies indicated as the new cancer treatment, a new heated competition is expected in the antibody market.
While MSD and Ono have acquired approvals for anti-PD-L1 immune antibodies, respective ‘Keytruda (generic name: pe...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
